Response to comment on “CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy”

European Journal of Clinical Pharmacology · Published 2026-05-14 · DOI 10.1007/s00228-026-04048-0

Authors (2)

Yande Kasolo, Robert M Cooper

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Kasolo, Y., Cooper, R. (2026). Response to comment on “CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy”. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-026-04048-0

Related articles

• The Effect of the combination therapy of statin and dapagliflozin, a selective inhibitor of sodium_glucose Co-transporter type 2, in the treatment of Ischemic heart disease with heart failure: A randomized controlled trial · European Journal of Clinical Pharmacology · 2026 · Same journal
• Acetaminophen exposure in an aging population and neurodegenerative outcomes · European Journal of Clinical Pharmacology · 2026 · Same journal
• Population pharmacokinetics of unbound imipenem in critically ill patients: a comparison of five renal function estimators for PK/PD-guided dosing · European Journal of Clinical Pharmacology · 2026 · Same journal
• Faster dementia progression was associated with use of potentially inappropriate medications · European Journal of Clinical Pharmacology · 2026 · Same journal
• Examining the risk of neurotoxicity in patients who receive unadjusted doses of oral beta-lactams in renal insufficiency: a retrospective cohort study · European Journal of Clinical Pharmacology · 2026 · Same journal
• Secondary data analysis of Adverse Drug Reactions reported by healthcare professionals and patients: interventions to manage ADRs of ACE inhibitors and ARBs · European Journal of Clinical Pharmacology · 2026 · Same journal
• Detection of intravenous drug physicochemical incompatibilities in clinical practice: e-Harvis compared to reference tools · European Journal of Clinical Pharmacology · 2026 · Same journal
• Effects of renal impairment on the pharmacokinetics, safety, and tolerability of pudexacianinium (ASP5354) after IV administration: a mechanistic exploration · European Journal of Clinical Pharmacology · 2026 · Same journal
• Authors response to the comments by Muhammad Salman, Muhammad Hammad Chola and Muhammad Hasan on our paper “prescribing patterns of glucagon like peptide-1 receptor agonists in the Swedish capital region: a register-based cross-sectional study” · European Journal of Clinical Pharmacology · 2026 · Same journal
• The role of Spanish clinical pharmacologists in economic evaluations of health technologies · European Journal of Clinical Pharmacology · 2026 · Same journal